Evidence suggests that immune checkpoint blockade immunotherapies targeting programmed cell death 1 (PD-1) or cytotoxic T-lymphocyte associated protein 4 (CTLA-4) are emerging as a new treatment option for lung cancer patients [21–23]. This evidence concerns the gene CTLA4 and lung cancer.